Online citations, reference lists, and bibliographies.
← Back to Search

5-Hydroxytryptamine And Its Role In Migraine.

J. Lance
Published 1991 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Platelet 5-hydroxytryptamine (5-HT) is diminished during migraine headache and the injection of reserpine, which releases 5-HT from body stores, induces a typical headache in migrainous subjects. The intravenous injection of 5-HT relieves established migraine headache, but causes side-effects of nausea, faintness, paraesthesia and dyspnoea. The 5-HT1-like agonist sumatriptan exerts the beneficial effects of 5-HT with minimal side-effects. Receptors for 5-HT are present in cranial arteries and are also widely distributed in the central nervous system, where they play a role in the neural control of the cranial circulation and endogenous pain control system. The pathophysiology of migraine involves interaction between these central pathways and cranial blood vessels. It is probable that many prophylactic agents exert their action by central 5-HT2 antagonism, whereas termination of an established attack of migraine depends upon constriction of cranial vessels mediated by 5-HT1 receptors.

This paper is referenced by
Goshuyuto, a traditional Japanese medicine for migraine, inhibits platelet aggregation in guinea-pig whole blood.
T. Hibino (2008)
Nitric Oxide, Perivascular Neural Transmission, and Migraine
J. Olesen (2000)
Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine
P. Tfelt-Hansen (2013)
Disturbances of Pain Perception in Primary Headache: Migraine, Tension-type, and Cluster Headaches
A. Pielsticker (2004)
Headache recurrence after subcutaneous sumatriptan
C. Dahlöf (1992)
The 5-HT1-Like Agonist Sumatriptan has a Significant Effect in Chronic Tension-Type Headache
J. Brennum (1992)
The preclinical toxicological evaluation of sumatriptan
K. Owen (1995)
Serotonin1B receptors: from protein to physiological function and behavior
Y. Sari (2004)
Multiple pharmacological and toxicological investigations on Tanacetum parthenium and Salix alba extracts: Focus on potential application as anti-migraine agents.
V. di Giacomo (2019)
Chronic buspirone treatment decreases 5-HT1B receptor densities and the serotonin transporter but increases the density of 5-HT2A receptors in the bulbectomized rat model of depression: an autoradiographic study
Hiroki Sato (2010)
Sumatriptan Clinical Pharmacokinetics
A. K. Scott (1994)
Bedeutung des serotoninergen Systems für die Pathophysiologie der Migräne
V. Limmroth (1994)
MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT1B receptor agonist, on motor control but not sleep inhibition
Norbert Gyongyosi (2008)
Sumatriptan in the treatment of migraine
M. Ferrari (1993)
Meta-analysis of 5-hydroxytryptamine type 2A receptor polymorphisms and migraine susceptibility
Jian-Ming Peng (2014)
18 – Pain Patients
Shamim H. Nejad (2010)
No Direct Association of Serotonin Transporter (STin2 VNTR) and Receptor (HT 102T>C) Gene Variants in Genetic Susceptibility to Migraine
G. Joshi (2010)
Levels of circulating homocysteine, vitamin B6, vitamin B12, and folate in different types of open-angle glaucoma
B. Turgut (2010)
5-Hydroxytryptophan: a clinically-effective serotonin precursor.
T. Birdsall (1998)
Platelets and migraine.
E. Danese (2014)
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine
P. Tfelt-Hansen (2017)
Looking beyond 5-HT(3) receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting.
Kevin D. Johnston (2014)
Response of the middle cerebral artery to serotonin
R. Mirzoyan (2006)
Synthesis and Characterization of Potential Impurities of the Antimigraine Drug, Rizatriptan Benzoate
P. Seetharama Sarma (2008)
Tanacetum parthenium and Salix alba (Mig-RL®) Combination in Migraine Prophylaxis
R. Shrivastava (2006)
Pathophysiology of Headaches with a Prominent Vascular Component
J. Pareja (1996)
Function of the Peripheral Serotoninergic Pathways in Migraine: A Proposal for An Experimental Model
P. Martelletti (1994)
Patent Update: 5-HT1Like and 5-HT1D-Agonists as Treatments for Migraine
T. Ward (1993)
Atypical facial pain: A double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan.
S. Harrison (1997)
A Pivotal Role of Nitric Oxide in Migraine Pain
L. Thomsen (1997)
Rabbit isolated renal artery contractions by some tryptamine derivatives, including 2‐methyl‐5‐HT, are mediated by a 5‐HT1‐like receptor
S. Tadipatri (1992)
Effect and mechanism of senkyunolide I as an anti‐migraine compound from Ligusticum chuanxiong
Y. Wang (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar